|1.||Hoever, Petra: 7 articles (05/2014 - 01/2011)|
|2.||Dingemanse, Jasper: 7 articles (05/2014 - 01/2011)|
|3.||Hoyer, Daniel: 4 articles (12/2013 - 12/2012)|
|4.||Steiner, Michel A: 3 articles (04/2015 - 04/2013)|
|5.||Jenck, Francois: 3 articles (04/2015 - 04/2013)|
|6.||Jacobson, Laura H: 3 articles (12/2013 - 01/2013)|
|7.||Fendt, Markus: 3 articles (10/2013 - 12/2012)|
|8.||Gee, Christine E: 3 articles (10/2013 - 12/2012)|
|9.||Gehin, Martine: 2 articles (05/2014 - 01/2014)|
|10.||Cruz, Hans Gabriel: 2 articles (05/2014 - 01/2014)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
11/01/2014 - "Several compounds (almorexant, SB-649868, suvorexant) have been in advanced clinical trials for treating primary insomnia. "
06/01/2013 - "These findings provide a solid basis to study the effects of almorexant in elderly patients with insomnia."
01/01/2014 - "The DORA almorexant demonstrated significant improvements in a number of clinically relevant sleep parameters in animal models and in patients with insomnia but its development was halted. "
09/01/2010 - "Another recent pharmacological agent for insomnia is almorexant, which new mechanism of action involves antagonism of hypocretinergic system, thus inducing sleep. "
12/01/2013 - "Less than 10years later, the first orexin antagonist, almorexant, a dual orexin receptor antagonist (DORA), was reported to be effective in inducing sleep in volunteers and insomnia patients. "
04/01/2014 - "This study in humans investigating single doses of almorexant is the first to explore and show abuse liability of a DORA, a class of compounds that is not only promising for the treatment of sleep disorders, but also of addiction."
01/01/2012 - "Almorexant, a dual orexin/hypocretin R(1) and R(2) receptor antagonist, has proven effective in preclinical studies in promoting sleep in animal models and was in Phase III clinical trials for sleep disorders. "
10/10/2013 - "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical trials in volunteers and primary insomnia patients. "
01/01/2013 - "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, SB-649868, suvorexant (MK-4305), and filorexant (MK-6096), have shown promise for the treatment of insomnias and sleep disorders. "
01/01/2012 - "Almorexant was well tolerated; the main observed adverse events were somnolence and fatigue. "
05/01/2014 - "Higher almorexant exposure was associated with an increased incidence of typical almorexant-related adverse events such as fatigue (both studies) and somnolence (ketoconazole study only). "
|4.||Nervous System Diseases (Neurological Disorders)
|5.||Body Weight (Weight, Body)
|4.||Serotonin (5 Hydroxytryptamine)
|6.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|8.||1- (2- methylbenzoxazol- 6- yl)- 3- (1,5)naphthyridin- 4- yl urea